Suppr超能文献

曲马多注射和局部应用于下颌第三磨牙拔除术的疗效和安全性:当前证据的定性系统评价。

Efficacy and safety of parenteral and local application of tramadol in mandibular third molar extraction: a qualitative systematic review of current evidence.

机构信息

Department of Clinical Pharmacology, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Department of Anesthesiology and Critical Care, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki,, Thessaloniki, Greece.

出版信息

Oral Maxillofac Surg. 2024 Jun;28(2):499-513. doi: 10.1007/s10006-023-01179-x. Epub 2023 Aug 29.

Abstract

PURPOSE

To assess the efficacy and safety of perioperative parenteral administration or submucosal infiltration of tramadol for perioperative pain control on the basis of pain intensity or analgesics consumption and perioperative outcomes in mandibular third molar surgery.

MATERIAL-METHODS: An electronic database search was conducted up to 10 November 2022 to retrieve all randomized controlled trials (RCTs), assessing the analgesic efficacy of parenteral use of tramadol implemented as an adjunct to local anesthesia or intraoperative sedation/general anesthesia, in surgical extraction of mandibular third molars. Modified Jadad scale and Cochrane bias tool were used for the qualitative appraisal.

RESULTS

Nineteen RCTs were selected for qualitative analysis. Nine studies involved intravenous, and 5 intramuscular administration of tramadol, while 5 evaluated submucosal infiltration with tramadol. Intravenous or intramuscular tramadol provided a weaker analgesic effect compared with non-steroidal anti-inflammatory drugs (NSAIDs), while intravenous tramadol induced an enhanced analgesic effect than oral tramadol. Parenteral administration of tramadol improved the quality of postoperative analgesia versus placebo. No notable adverse effects were recorded.

CONCLUSIONS

Parenteral or submucosal infiltration of tramadol constitutes an effective and safe alternative analgesic approach in surgical extraction of mandibular third molars, yet the nociceptive effect of this analgesic modality could not supersede that of NSAIDs.

TRIAL REGISTRATION

PROSPERO No CRD42021227574.

摘要

目的

基于疼痛强度或镇痛药消耗以及下颌第三磨牙手术的围手术期结局,评估围手术期给予曲马多的肠外给药或黏膜下浸润在围手术期疼痛控制方面的疗效和安全性。

材料-方法:截至 2022 年 11 月 10 日,进行了电子数据库检索,以检索所有评估静脉内给予曲马多作为局部麻醉或术中镇静/全身麻醉辅助用药,在外科拔除下颌第三磨牙时的镇痛效果的随机对照试验(RCT)。使用改良 Jadad 量表和 Cochrane 偏倚工具进行定性评估。

结果

选择了 19 项 RCT 进行定性分析。9 项研究涉及曲马多的静脉内和肌内给药,而 5 项研究评估了曲马多的黏膜下浸润。与非甾体抗炎药(NSAIDs)相比,静脉内或肌内给予曲马多提供的镇痛效果较弱,而静脉内给予曲马多产生的镇痛效果强于口服曲马多。与安慰剂相比,给予曲马多可改善术后镇痛质量。未记录到明显的不良反应。

结论

在外科拔除下颌第三磨牙时,给予曲马多的肠外或黏膜下浸润是一种有效且安全的替代镇痛方法,但这种镇痛方式的痛觉效果不能超过 NSAIDs。

试验注册

PROSPERO(国际前瞻性注册数据库)编号 CRD42021227574。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验